Today, the last trading day of the month, there are in total 53,384,558 shares outstanding and 66,912,440 votes in Karolinska Development. Of these, 1,503,098 are series A shares with 15,030,980 votes and 51,881,460 are shares and votes of series B.
Karolinska Development AB (publ) discloses the information in this press release according to the Swedish Securities Markets Act and/or the Swedish Financial Trading Act. The information was provided for public release on December 30, 2014 at 9.00am.
For further information, please contact:
Bruno Lucidi, CEO, Karolinska Development AB
Phone: +46 (0) 8 524 860 70, e-mail: Bruno.lucidi@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into differentiated products that can be partnered. The business model is to: SELECT the most commercially attractive medical innovations that can potentially satisfy unmet medical needs; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. For more information, please visit www.karolinskadevelopment.com.
Karolinska Development is listed on NASDAQ OMX (KDEV). Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.
